Innovus Pharma Launches Zestra® Multi-Dose Form for Female Sexual Arousal in the U.S.

Clinically proven to increase arousal desire and sexual satisfaction
in women, Zestra
® will be launched on Innovus’ Beyond Human Sales
and Marketing Platform

Pharmaceuticals, Inc.
(“Innovus Pharma”) (OTCQB Venture Market:
INNV), an emerging commercial-stage pharmaceutical company that delivers
safe, innovative and effective over-the-counter medicine and consumer
care products to improve men’s and women’s health and respiratory
diseases, today announced the launch of Zestra®
Multi-dose in the U.S. Approximately 43% of women age 18 to 59, or 50
million, experience some form of Female Sexual Dysfunction (FSD)
according to a
published study
. (Laumann, E.O. et al. Sexual Dysfunction in the
United States: Prevalence and Predictors. JAMA, Feb. 10, 1999. vol. 281,
No. 6.537-542). The FSD market is estimated to be more
than $1 billion per year

“Zestra® is the fourth Innovus product to be launched using our acquired
Beyond Human sales and marketing platform and we currently believe the
product could generate an additional $1.5 million a year in revenues,
adding to the revenues already being generated by the retail and online
sales of the product along with our revenues for Vesele®,
Sensum+® and RecalMax™ dietary supplements,” said Innovus CEO Dr.
Bassam Damaj
. “This launch is one more step towards achieving our
2017 corporate goals of $15 million in revenue and profitability.”

The product is available through
and through the Beyond Human print and online platform reaching between
20-30 million Americans on a monthly basis.

About Zestra® and FSI/AD

Zestra® is a patented blend of natural oils clinically-proven in
double-blind placebo-controlled clinical trials in 276 women to increase
in a statistical significant manner the arousal, desire and sexual
satisfaction in FSI/AD women. Zestra® is the first NHP product to
receive approval for the indication of FSI/AD in Canada. To date, no
product has been approved to treat FSI/AD, a persistent or recurring
inability to attain or maintain adequate sexual excitement until the
completion of a sexual activity. The diagnosis can also refer to an
inadequate lubrication-swelling response normally present during arousal
and sexual activity causing personal distress. Published papers on the
FSI/AD market size estimate it to be equal or larger than the market for
erectile dysfunction in males, and possibly larger.

For more information on Zestra® visit

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC
and consumer products for men’s and women’s health and respiratory
diseases. The Company generates revenues from its lead products (a) BTH®
Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for
female arousal and (d) EjectDelay® for premature ejaculation and has an
additional five marketed products in this space, including (e) Sensum+®
for the indication of reduced penile sensitivity, (f) Zestra Glide®,
(g)Vesele® for promoting sexual and cognitive health, (h) Androferti®
(in the US and Canada) to support overall male reproductive health and
sperm quality, (i) BTH Vision Formula, (j) BTH Blood Sugar, among others
and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is
approved by the U.S. FDA.

For more information, go to,,,,,,,,,

Innovus Pharma’s Forward-Looking Safe Harbor:

Statements under the Private Securities Litigation Reform Act, as
amended: with the exception of the historical information contained in
this release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may individually or
mutually impact the matters herein described for a variety of reasons
that are outside the control of the Company, including, but not limited
to, projected revenues from the Zestra® product, projected online
subscribers, estimated market for its products, and statements about
achieving its other development, growth, commercialization, financial
and staffing objectives. Readers are cautioned not to place undue
reliance on these forward-looking statements as actual results could
differ materially from the forward-looking statements contained herein.
Readers are urged to read the risk factors set forth in the Company’s
most recent annual report on Form 10-K, subsequent quarterly reports
filed on Form 10-Q and other filings made with the SEC. Copies of these
reports are available from the SEC’s website or without charge from the


Chesapeake Group
Kevin Holmes, 410-825-3930